GlassScriptPhysician profile
Kanika Arora
NPI 1063778322
$1,997.79
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,615 · 2020: $199 · 2021: $33.35 · 2022: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,131.50 | 2019 | |
| Ucb, INC. | $142.25 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $121.73 | 2022 | |
| Genzyme Corporation | $106.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $103.67 | 2019-2020 | |
| Eisai INC. | $78.09 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $62.14 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $47.35 | 2019-2020 | |
| Abbvie INC. | $43.66 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $41.00 | 2019 | |
| Biogen, INC. | $29.87 | 2019-2020 | |
| Amgen INC. | $20.73 | 2019 | |
| Upsher-Smith Laboratories LLC | $19.32 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.47 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.96 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $11.44 | 2019 | |
| Acadia Pharmaceuticals INC | $11.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanika Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.